[go: up one dir, main page]

Cipriano et al., 2020 - Google Patents

Nevirapine biotransformation insights: an integrated in vitro approach unveils the biocompetence and glutathiolomic profile of a human hepatocyte-like cell 3D model

Cipriano et al., 2020

View HTML
Document ID
15310313578743450087
Author
Cipriano M
Pinheiro P
Sequeira C
Rodrigues J
Oliveira N
Antunes A
Castro M
Marques M
Pereira S
Miranda J
Publication year
Publication venue
International Journal of Molecular Sciences

External Links

Snippet

The need for competent in vitro liver models for toxicological assessment persists. The differentiation of stem cells into hepatocyte-like cells (HLC) has been adopted due to its human origin and availability. Our aim was to study the usefulness of an in vitro 3D model of …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Similar Documents

Publication Publication Date Title
Kammerer Three-dimensional liver culture systems to maintain primary hepatic properties for toxicological analysis in vitro
Cipriano et al. Nevirapine biotransformation insights: an integrated in vitro approach unveils the biocompetence and glutathiolomic profile of a human hepatocyte-like cell 3D model
Kakuni et al. Chimeric mice with humanized livers: a unique tool for in vivo and in vitro enzyme induction studies
Knöspel et al. In vitro model for hepatotoxicity studies based on primary human hepatocyte cultivation in a perfused 3D bioreactor system
Grangeon et al. Determination of CYP450 expression levels in the human small intestine by mass spectrometry-based targeted proteomics
Lee et al. Microtechnology-based multi-organ models
Zhu et al. Effects of p-Cresol on oxidative stress, glutathione depletion, and necrosis in heparg cells: comparisons to other uremic toxins and the role of p-cresol glucuronide formation
De Siervi et al. Liver organoids as an in vitro model to study primary liver cancer
Mun et al. Effect of microbial short-chain fatty acids on CYP3A4-mediated metabolic activation of human pluripotent stem cell-derived liver organoids
Bouwmeester et al. Drug metabolism of hepatocyte-like organoids and their applicability in in vitro toxicity testing
Holmgren et al. Characterization of human induced pluripotent stem cell-derived hepatocytes with mature features and potential for modeling metabolic diseases
Lőrincz et al. The performance of HepG2 and HepaRG systems through the glass of acetaminophen-induced toxicity
Choi et al. Flow-based three-dimensional co-culture model for long-term hepatotoxicity prediction
Li et al. Human pluripotent stem cell-derived hepatocyte-like cells and organoids for liver disease and therapy
Vilas-Boas et al. Primary human hepatocyte spheroids as tools to study the hepatotoxic potential of non-pharmaceutical chemicals
Ruoß et al. Cell-type-specific quantification of a scaffold-based 3D liver co-culture
Kim et al. Human embryonic stem cell-derived Wilson’s disease model for screening drug efficacy
Lonati et al. Quantitative metabolomics of tissue, perfusate, and bile from rat livers subjected to normothermic machine perfusion
TR et al. In vitro hepatic models to assess herb–drug interactions: approaches and challenges
Kulkeaw et al. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases
Gramignoli et al. Effects of pro-inflammatory cytokines on hepatic metabolism in primary human hepatocytes
Stern et al. Microphysiological models for mechanistic-based prediction of idiosyncratic DILI
Choi et al. Validating Well-Functioning Hepatic Organoids for Toxicity Evaluation
Park et al. Inhibitory effect of AB-PINACA, indazole carboxamide synthetic cannabinoid, on human major drug-metabolizing enzymes and transporters
Messner et al. Single cell gene expression analysis in a 3D microtissue liver model reveals cell type-specific responses to pro-fibrotic TGF-β1 stimulation